Liquidia (NASDAQ:LQDA) Insider Jason Adair Sells 13,548 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 13,548 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $507,101.64. Following the completion of the transaction, the insider owned 184,174 shares in the company, valued at $6,893,632.82. This represents a 6.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jason Adair also recently made the following trade(s):

• On Monday, December 1st, Jason Adair sold 693 shares of Liquidia stock. The stock was sold at an average price of $32.19, for a total transaction of $22,307.67.
• On Tuesday, November 18th, Jason Adair sold 35,656 shares of Liquidia stock. The shares were sold at an average price of $30.03, for a total transaction of $1,070,749.68.
• On Monday, October 27th, Jason Adair sold 692 shares of Liquidia stock. The shares were sold at an average price of $22.93, for a total value of $15,867.56.

Liquidia Stock Up 4.1%

NASDAQ:LQDA opened at $38.09 on Wednesday. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. Liquidia Corporation has a 12-month low of $11.26 and a 12-month high of $39.29. The stock’s fifty day simple moving average is $32.14 and its 200-day simple moving average is $25.58. The firm has a market capitalization of $3.31 billion, a P/E ratio of -26.45, a P/E/G ratio of 1.22 and a beta of 0.48.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The business had revenue of $54.34 million during the quarter, compared to the consensus estimate of $18.86 million. The company’s quarterly revenue was up 1106.7% compared to the same quarter last year. Equities research analysts expect that Liquidia Corporation will post -1.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LQDA has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of Liquidia from a “hold” rating to a “buy” rating in a report on Saturday. Wells Fargo & Company assumed coverage on shares of Liquidia in a report on Monday, October 20th. They issued an “overweight” rating and a $31.00 price target for the company. Raymond James Financial reaffirmed a “strong-buy” rating and set a $47.00 price objective on shares of Liquidia in a research note on Tuesday, November 4th. BTIG Research reiterated a “buy” rating and set a $49.00 target price on shares of Liquidia in a report on Friday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Liquidia currently has an average rating of “Moderate Buy” and an average price target of $39.67.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Short interest fell materially in December — short interest declined about 18.1% to ~10.71M shares as of Dec. 31 (about 17.6% of shares outstanding), lowering potential downward pressure from short sellers and reducing immediate squeeze risk.
• Neutral Sentiment: Reported short-interest data for Jan. 12 appears inconsistent (shows 0 shares / NaN change), which looks like a reporting glitch and should be treated as unreliable until corrected.
• Negative Sentiment: CEO Roger Jeffs sold 66,610 shares at an average of $37.43 for roughly $2.49M, reducing his direct stake by ~6.0%. SEC Filing – Roger Jeffs
• Negative Sentiment: CFO Michael Kaseta sold 36,932 shares at $37.43 for about $1.38M, a ~9.5% reduction in his holding. SEC Filing – Michael Kaseta
• Negative Sentiment: General Counsel Russell Schundler sold 27,289 shares at $37.43 for about $1.02M, a ~4.5% stake reduction. SEC Filing – Russell Schundler
• Negative Sentiment: Insider Rajeev Saggar sold 21,142 shares at $37.43 (~$791k), cutting his holdings by ~10.7%. SEC Filing – Rajeev Saggar
• Negative Sentiment: Scott Moomaw sold 20,533 shares at $37.43 (~$769k), an ~11.7% reduction in his stake. SEC Filing – Scott Moomaw
• Negative Sentiment: CAO Dana Boyle sold 11,047 shares at $37.43 (~$413k), a ~6.6% reduction. SEC Filing – Dana Boyle
• Negative Sentiment: Insider Jason Adair sold 13,548 shares at $37.43 (~$507k), and Sarah Krepp sold 13,165 shares (~$493k); both reduced holdings by mid-single-digit to high-single-digit percentages. SEC Filing – Jason Adair SEC Filing – Sarah Krepp

Hedge Funds Weigh In On Liquidia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC increased its holdings in Liquidia by 46.7% during the 4th quarter. SG Americas Securities LLC now owns 54,696 shares of the company’s stock worth $1,886,000 after purchasing an additional 17,407 shares in the last quarter. Insight Wealth Strategies LLC acquired a new position in shares of Liquidia during the fourth quarter worth about $4,891,000. Tudor Investment Corp ET AL bought a new position in shares of Liquidia during the third quarter worth about $1,536,000. FNY Investment Advisers LLC acquired a new stake in Liquidia in the 3rd quarter valued at approximately $34,000. Finally, Caxton Associates LLP acquired a new stake in Liquidia in the 3rd quarter valued at approximately $389,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).